The Mako Robotic-Arm Assisted Surgery System from Stryker Corp - precise cuts, consistent knee and hip replacements
24.06.2026 - 00:53:01 | ad-hoc-news.de
Reviewed: ad hoc news New Release & Launch desk. Edited and checked on 2026-06-24, 00:50. Details in the imprint.
When a surgeon grips the Mako Robotic-Arm Assisted Surgery System handle, the metal feels cool and steady, and the arm resists if they drift beyond the virtual cutting boundary. That tactile feedback is the core promise of Stryker’s flagship orthopedic robot.
How Mako plans a joint
Mako starts with a pre-operative CT scan that is turned into a patient-specific 3D model of the hip or knee, allowing detailed planning of implant size, alignment and bone cuts before the patient enters the operating room. Surgeons can preview how different component positions affect soft-tissue balance and range of motion on screen.
In the operating room, optical trackers on the leg and on the robotic arm help the system register the patient’s actual anatomy to the pre-op CT plan, so that virtual landmarks match physical bone within a defined tolerance. Stryker says this real-time registration is critical to keep the haptic boundary accurate around the joint.
What the robotic arm does
During bone preparation, the surgeon still holds the burr or saw, but Mako’s robotic arm constrains movement within a 3D envelope, providing haptic feedback and automatically stopping the cutter at the edge of the planned resection zone. In practice, this means the hand feels a clear “wall” when trying to push past the allowed area.
For Mako Total Knee and Partial Knee applications, the system helps remove just enough bone to fit Stryker’s Triathlon implant family while aiming to maintain ligament balance throughout flexion. In Mako Total Hip, the arm guides acetabular preparation and cup insertion to the planned inclination and anteversion, with on-screen angles updating in real time.
Background on Stryker Corp shares
Mako and Stryker’s orthopedic robots are central to the growth story that many investors track in Stryker Corp shares.
Why hospitals buy Mako
In recent investor presentations, Stryker CEO Kevin Lobo has highlighted Mako installed base growth and procedure volumes as a strategic driver within the company’s MedSurg and Neurotechnology segment. Hospitals tend to position the system as a differentiator for elective joint replacement programs.
The company reports that Mako-supported hip and knee procedures have surpassed one million globally, underlining the system’s commercial traction in the United States and selected international markets. Many large centers in the US promote their Mako suites directly in patient-facing marketing materials.
Clinical results and limits
Peer-reviewed studies cited by Stryker associate Mako Total Knee with more consistent component alignment and potentially lower rates of outliers compared with manual techniques, though long-term outcome data are still developing. A number of surgeons also report smoother early rehabilitation when soft-tissue balancing is more predictable.
At the same time, the learning curve is real: operating room teams must adapt workflows, and set-up can extend theater time during the adoption phase. Surgeons with decades of manual experience sometimes question whether the added capital and service costs translate into enough clinical advantage for every case.
Costs, service and footprint
Mako is a capital-intensive system that requires not only the robotic arm platform but also compatible implants, dedicated saws and burrs, and annual service contracts that lock customers into Stryker’s ecosystem. List prices are not publicly detailed, but US hospital executives often describe the investment as comparable to other premium surgical robots.
The physical footprint is that of a sizeable tower and robotic arm unit which must be wheeled between theaters or dedicated to one room. For smaller orthopedic departments, this can be a constraint, especially when caseloads are uneven and storage space is tight.
Where Mako fits in the market
Mako competes with robotic and navigation platforms from Zimmer Biomet, Smith+Nephew and DePuy Synthes, among others, in a race to standardize more of the joint replacement process. Stryker leans heavily on the integration between the system and its Triathlon knee and Accolade and Insignia hip portfolios.
For investors, the key is that every installed Mako robot typically brings a long tail of high-margin implant and instrument revenue, reinforcing Stryker’s recurring business model. All told, the system is less about futuristic robots and more about locking in relationships with high-volume joint replacement centers.
Stryker on the market
Stryker Corp, headquartered in Kalamazoo, Michigan, lists its shares on the New York Stock Exchange under the ticker SYK, and the development of its robotic and orthopedic portfolio, including the Mako platform, remains a central theme in how the Stryker share price is viewed by many market participants.
Key facts on Stryker’s Mako system
- Product: Mako Robotic-Arm Assisted Surgery System
- Manufacturer: Stryker Corporation
- Category: New release/launch - orthopedic surgical robot
- Launch: Initial partial knee clearance 2005, expanded for total hip 2015 and total knee 2015-2017 (US FDA clearances)
- RRP / Price: Not publicly listed; hospital contracts typically bundle capital system, implants and service in high six- to seven-figure US dollar ranges
- Availability: Installed in hospitals and surgical centers primarily in the United States, with selected placements in Europe, Asia-Pacific and Latin America
- Target group: Orthopedic surgeons and hospitals performing high volumes of total knee, partial knee and total hip arthroplasty
- Highlight / USP: CT-based 3D planning combined with haptic-guided robotic bone preparation for Stryker’s own implant lines
This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.
